5 Recent Cancer Drug Approvals That Patients May Have Missed

Published on: 

The Food and Drug Administration has had a busy couple of weeks, approving several agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

The Food and Drug Administration (FDA) has approved several drugs in the cancer space over the last several weeks.

The agency is expected to continue to approve more oncology therapies over the summer, but in case you missed it, CURE® compiled a list of five recent FDA approvals.

Truseltiq for the Treatment of Metastatic Cholangiocarcinoma

Among 108 patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement, treatment with Truseltiq (infigratinib) induced an overall response rate (percentage of patients with a partial or complete response to treatment) of 23%. READ MORE.

Lumakras to Treat Subgroup of Patients with Non-Small Cell Lung Cancer

Objective response rate (defined as the proportion of patients whose tumor was reduced or destroyed) was 36%, of whom 58% had a duration of response of at least six months. READ MORE.

Opdivo for Adjuvant Treatment of Esophageal and Gastroesophageal Junction Cancer

Median disease-free survival was greater in patients treated with Opdivo (nivolumab) versus those treated with placebo. This was also observed in patients with squamous cell carcinoma and those with adenocarcinoma. READ MORE.

Keytruda Combo Regimen for Stomach Cancer Subtypes

Treatment with Keytruda (pembrolizumab) plus trastuzumab, fluoropyrimidine-and platinum-containing chemotherapy resulted in an overall response rate of 74% compared with 52% in those assigned a placebo. READ MORE.

Rybrevant for Certain Group of Patients with Non-Small Cell Lung Cancer

Patients who received Rybrevant (amivantamab-vmjw) achieved an overall response rate of 40%. READ MORE.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.